I'm LongbridgeAI, I can summarize articles.DualityBio (9606.HK) fell more than 4% in Hong Kong trading to HK$99.95, hitting a record low since listing.
The stock is down 41.21% over the past ten sessions and down 66.48% year to date. It sits 73.47% below its 52-week high of HK$376.80. Volume was 3.27 times its average.
The Hang Seng Index is up 0.95% over the past five sessions and down 8.58% year to date.
The company and BioNTech announced that the global Phase III DYNASTY-Breast02 trial for patritumab deruxtecan met its primary endpoint, showing a statistically significant improvement in progression-free survival versus chemotherapy, though overall survival data remain immature. The incidence of interstitial lung disease was higher than in prior trials, suggesting limited potential clinical benefit for specific patient populations given the current treatment landscape.
Separately, DualityBio is advancing its STAR Market IPO application. The company has accumulated losses of 4.87 billion yuan over the past three and a half years and plans to raise 4.1 billion yuan to fund innovative drug development.
Based on public media reports. AI-generated; not investment advice.
